Detalhe da pesquisa
1.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36927527
2.
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kß Inhibition in PTEN Loss Melanoma.
Clin Cancer Res
; 25(21): 6406-6416, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371342
3.
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Clin Cancer Res
; 13(11): 3276-85, 2007 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17545533
4.
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Mol Cancer Ther
; 14(2): 461-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25504632
5.
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
J Thorac Oncol
; 8(12): 1529-37, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24389434